Fibrinolytic Profiles in Local Low-Dose Thrombolysis with Streptokinase and Recombinant Tissue Plasminogen Activator

Summary

Fibrinolytic parameters have been monitored in 44 patients undergoing local low-dose intra-arterial thrombolysis for acute peripheral arterial ischaemia. Streptokinase (Sk), at a dose of 5,000 units/hr with 250 units/hr heparin, was used in 23 patients and recombinant tissue plasminogen activator (r-tPA) at a dose of 0.5 mg/hr was used in 21 patients. Successful lysis was seen in 18 (86%) patients following r-tPA and in 15 (65%) patients following streptokinase. There were 4 minor haematomas in each group usually at the catheter entry site. Both agents produced a systemic effect, which was still seen 12 hours post-infusion. However, that produced by r-tPA was delayed and significantly reduced compared to that produced by Sk.

These results confirm the relative fibrin specificity of r-tPA. When used as a continuous low-dose intra-arterial infusion, r-tPA offers a significantly lower, potentially safer, systemic effect than conventional therapy with streptokinase.

Keywords

Acute peripheral ischaemia - Systemic fibrinolysis - Thrombolys - Recombinant tissue plasminogen activator - Streptokinase

• References

• 1 Aldrich MS, Sherman SA, Greenberg HS. Cerebrovascular complications of streptokinase infusion. JAMA 1985; 253 (12) 1777-1779
• 2 Amery A, Deloof W, Vermylen J, Verstraete M. Outcome of recent thromboembolic occlusions of limb arteries treated with steptokinase. Br Med J 1970; 4: 639-644
• 3 Dotter CT, Rosch J, Seamann AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31-37
• 4 Hess H, Ingridch H, Mietaschk A, Rath H. Local low dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med 1982; 307 (26) 1627-1630
• 5 Astrup A. Tissue activators of plasminogen. Fed Proc 1966; 25: 42-51
• 6 Rijken DC, Wijngaards G, Zaal-de Jong M, Wellbergen J. Purification and partial characterisation of plasminogen activator from human uterine tissue. Biochem Biophys Res Commun 1979; 580: 140-153
• 7 Pennica D, Holmes WW, Kohr WJ. et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 291: 214-221
• 8 Collen D, Stassen JJ, Marafiro B. et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 23: 146-152
• 9 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasma inhibitor in human blood by means of a specific tripeptide substrate. Scand J Clin Invest 1977; 37: 403-409
• 10 Soria J, Soria C, Samama M. Dosage du plasminogène à l’aide d’un substrat chromogène tripeptidique. Pathol Biol 1976; 24: 725-729
• 11 Clauss vonA. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 12 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Pathol 1958; 11: 403-405
• 13 Poliwoda H. Treatment of chronic arterial occlusions with streptokinase. J Clin Pathol 1972; 25: 642-643
• 14 Conard J, Samama M, Milochevitch R, Horellou MM, Chabrun B, Prestat J. Complications hemorragiques au cours de 98 traitements par la streptokinase. Nouv Presse Med 1979; 8 (16) 1319-1320
• 15 Smith RAG, Dupe RR, English PD, Green J. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemostas 1982; 47 (03) 269-274
• 16 Dupe RJ, Green J, Smith RA. Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. Thromb Haemostas 1985; 53: 56-59
• 17 Prowse CV, Hornsey V, Ruckley CC, Boulton FE. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers. Thromb Haemostas 1982; 47: 132-135
• 18 Eamshaw JJ, Westby J, Makin GG, Hopkinson BR. The systemic fibrinolytic effect of BRL 26921 during the treatment of acute peripheral arterial occlusions. Thromb Haemostas 1986; 55 (02) 259-262
• 19 Earnshaw JJ, Westby J, Makin GG, Hopkinson BR. Low dose intraarterial streptokinase and acylated plasminogen-streptokinase activator complex: a retrospective review of two thrombolytic regimes in recent peripheral arterial ischaemia. Eur J Vase Surg 1987; 1: 151-158
• 20 Collen D. Tissue-type plasminogen activator therapeutic potential in thrombotic disease states. Drugs 1986; 31: 1-5
• 21 Graor RA, Risius B, Lucas FF, Young JR, Ruschhaupt WF, Beven EG, Grossbard EB. Thrombolysis with recombinant tissue-type plasminogen activator in patients with peripheral artery and bypass occlusions. Circulation 1986; 74 suppl (Suppl. 01) 15-20
• 22 Risius B, Graor RR, Geisinger MA, Zelch MG, Lucas FV, Young JR. Thrombolytic therapy with recombinant tissue-type plasminogen activator: A comparison of two doses. Radiology 1987; 164: 465-468
• 23 Eamshaw JJ, Gregson RH S, Makin GS, Hopkinson BR H. A dose ranging study of recombinant tissue plasminogen activator in peripheral arterial thrombosis. Presented at SRS. Leeds: 1987
• 24 Earnshaw JJ, Berridge DC, Hopkinson BR, Makin GS. Thrombolysis in acute peripheral arterial ischaemia: which patient, which drug, does it Work and does it last. Br J Surg 1988; 75 (04) 395